Navigation Links
Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
Date:2/13/2009

December 31, December 31, 2008 2007 2008 2007 Operating expenses: Research and development $2,986 $4,462 $6,189 $9,702 General and administrative 1,874 1,756 5,313 3,823 Total operating expenses 4,860 6,218 11,502 13,525 Loss from operations (4,860) (6,218) (11,502) (13,525) Interest and other, net 26 358 126 835 Net loss $(4,834) $(5,860) $(11,376) $(12,690) Basic and diluted net loss per share $(0.19) $(0.23) $(0.44) $(0.49) Shares used to compute basic and diluted net loss per share 26,034 25,968 26,025 25,977 Condensed Balance Sheets (unaudited, in thousands) December 31, June 30, 2008 2008 Assets Cash, cash equivalents and marketable securities* $12,917 $16,755 Other current assets 759 401 Total current assets 13,676 17,156 Property and equipment, net 537 688 Other noncurrent assets 290 523 $14,503 $18,367 Liabilities and stockholders' equity Current liabilities $1,902 $1,851 Note payable to related party - current 4,500 - Long-term obligations 69 71 Stockholders' equity 8,032 16,445
'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
2. Pharmacyclics Secures $5.0 Million in Debt Financing
3. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
4. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
5. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
6. Pharmacyclics Announces It Received Nasdaq Notification
7. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
8. YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
9. Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results
10. Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
11. Corgenix Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... City, Utah (PRWEB) August 27, 2014 ... that will expand its current Salt Lake City manufacturing ... underway outside of Utah to ultimately create 1,000 new ... 20 years. , “Utah is home to hardworking ... whom can be credited with Varian’s success in the ...
(Date:8/27/2014)... Aug. 27, 2014 Rhythm, a biopharmaceutical company ... deficiencies that result in metabolic disorders, announced today that ... with the U.S. Securities and Exchange Commission (SEC) relating ... its common stock. The number of shares to be ... not yet been determined. Citigroup and Cowen ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a ... its catalogue: Global Biodegradable Packaging ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html About Biodegradable Packaging ... readily decomposed by the action of microorganisms. ... in terms of raw materials, production technology, ...
(Date:8/27/2014)... mysteries is how plants survive impact by the ... rays, while using this energy for photosynthesis. The ... plant,s blades quickly dissipate the energy throughout the ... at DTU Physics have now managed to successfully ... bacteria contain light-absorbing proteins which play a role ...
Breaking Biology Technology:Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7DTU researchers film protein quake for the first time 2
... Ala. , May 12 Atherotech Inc. will exhibit its ... Scientific Sessions 2010. The meeting takes place May 13-16 at ... , , ... lipid test that routinely reports directly measured LDL-C, which is included in ...
... ,, RESEARCH TRIANGLE PARK, N.C. , May 12 ... Research Clinical Trials and Statistics Unit, is running the Intergroup Exemestane Study ... women with early breast cancer and a median follow-up period of 91 ... the data from multiple centers. , ...
... Indiana Seed Fund, Indiana ,s only targeted life sciences seed ... Indianapolis -based biotechnology start-up company focused on the development of ... , , , ... 5 million Americans suffer from Alzheimer,s disease (AD), a number that ...
Cached Biology Technology:Atherotech Emphasizes Predictive Value of VAP(R) Cholesterol Test at National Lipid Association Meeting 2Atherotech Emphasizes Predictive Value of VAP(R) Cholesterol Test at National Lipid Association Meeting 3Max Neeman International Signs Agreement for Data Management/EDC of Large Phase IV Trials from Multiple Sites 2BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimer's Disease 2BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimer's Disease 3BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimer's Disease 4
(Date:8/28/2014)... handful of bacterial culprits that may drive inflammatory bowel ... using patients, own intestinal immune responses as a guide. ... journal Cell . , Trillions of bacteria exist ... role in the development and progression of IBD. Yet ... species affect a person,s susceptibility to IBD and its ...
(Date:8/28/2014)... and his collaborators have developed an online analytic tool ... re-engineering cells for biomedical investigation. CellNet is a free-use ... stem cell engineering. Details of CellNet and its application ... papers in the journal Cell . , "This ... all types of cell-based investigations and can potentially offer ...
(Date:8/28/2014)... 28, 2014  Privacy Advocate and Senior Staff Attorney ... , joins the lineup of biometric and mobile commerce ... UnPlugged Executive Summit in Tampa, Florida ... announced speakers include Steven Rahman, Director, Technology and Strategy at ... Experian. The theme of this year,s event is Mobility ...
Breaking Biology News(10 mins):Yale study identifies possible bacterial drivers of IBD 2New tool aids stem cell engineering for medical research 2Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2
... clinic at the University of Michigan, neurologist Joseph Corey, M.D., ... to disease or injury. He sees the pain, ... conditions cause and wishes he could give patients more ... he heads to his research lab at the VA Ann ...
... Tom Bowman, chairman of Bowman Design Group and president ... Carbon Mitigation for Every Business" at the 2012 Behavior, ... original research and the success of own company,s green ... by 65% and decreased annual operating costs by $9000 ...
... HOUSTON (Nov. 7, 2012) Administering stem cells derived ... after a heart attack is safe but does not improve ... supported by the National Institutes of Health (NIH). ... Evaluation (TIME), mirror a previous related study, LateTIME, which found ...
Cached Biology News:Stem cells + nanofibers = Promising nerve research 2Stem cells + nanofibers = Promising nerve research 3Bone marrow stem cells do not improve short-term recovery after heart attack 2Bone marrow stem cells do not improve short-term recovery after heart attack 3
Human Carnosine Dipeptidase 1 Affinity Purified PAb...
... Polyoxyethylene Lauryl Ether ... 0.02% Kathon Preservative. Surfactant. ... in immunohistochemistry is 1 ... 35 solution added to ...
Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
MMP-1/8 (H-300)...
Biology Products: